AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 61(6), 1999, pp. 865-868
Copyright © 1999 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doherty, J.
Right arrow Articles by Cohen, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doherty, J.
Right arrow Articles by Cohen, J
Related Collections
Right arrow Vaccine
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 61, Issue 6, 865-868
Copyright © 1999 by American Society of Tropical Medicine and Hygiene

Research Articles


A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia

JF Doherty, M Pinder, N Tornieporth, C Carton, L Vigneron, P Milligan, WR Ballou, CA Holland, KE Kester, G Voss, P Momin, BM Greenwood, KP McAdam, and J Cohen

RTS,S is a novel pre-erythrocytic malaria vaccine based on the circumsporozoite surface protein (CSP) of Plasmodium falciparum linked to hepatitis B surface antigen (HBs) and combined with a novel adjuvant system (SBAS2). We have conducted a Phase I trial with three doses of this vaccine given at 0, 1, and 6 months to 20 semi-immune, adult, male volunteers in The Gambia to assess its safety and immunogenicity. Eighteen of the 20 volunteers completed the study. There were no clinically significant local or systemic adverse events following each vaccination. Hematologic and biochemical indices before and two weeks after each vaccination showed no evidence of toxicity. Antibody titers to both CSP and HBs showed a significant increase after vaccination; these were the largest after the third dose. We conclude that the RTS,S/SBAS2 vaccine induces no significant toxicity in this semi-immune population and produces significant increases in antibody titers to CSP.


This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
S. J. Jordan, O. H. Branch, J. C. Castro, R. A. Oster, and J. C. Rayner
Genetic Diversity of the Malaria Vaccine Candidate Plasmodium falciparum Merozoite Surface Protein-3 in a Hypoendemic Transmission Environment
Am J Trop Med Hyg, March 1, 2009; 80(3): 479 - 486.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
W. R. Ballou and C. P. Cahill
Two Decades of Commitment to Malaria Vaccine Development: GlaxoSmithKline Biologicals
Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 289 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
J. A. STOUTE, D. G. HEPPNER JR., C. J. MASON, J. SIANGLA, M. O. OPOLLO, K. E. KESTER, L. VIGNERON, G. VOSS, M. J. WALTER, N. TORNIEPORTH, et al.
Phase 1 safety and immunogenicity trial of malaria vaccine rts,s/as02a in adults in a hyperendemic region of Western kenya.
Am J Trop Med Hyg, July 1, 2006; 75(1): 166 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
O. J. A. E. Ophorst, K. Radosevic, M. J. E. Havenga, M. G. Pau, L. Holterman, B. Berkhout, J. Goudsmit, and M. Tsuji
Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice
Infect. Immun., January 1, 2006; 74(1): 313 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
W. R. BALLOU, M. AREVALO-HERRERA, D. CARUCCI, T. L. RICHIE, G. CORRADIN, C. DIGGS, P. DRUILHE, B. K. GIERSING, A. SAUL, D. G. HEPPNER, et al.
UPDATE ON THE CLINICAL DEVELOPMENT OF CANDIDATE MALARIA VACCINES
Am J Trop Med Hyg, August 1, 2004; 71(2_suppl): 239 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. S. WALSH, S. PICHYANGKUL, M. GETTAYACAMIN, P. TONGTAWE, C.-A. SIEGRIST, P. HANSUKJARIYA, K. E. KESTER, C. A. HOLLAND, G. VOSS, J. COHEN, et al.
SAFETY AND IMMUNOGENICITY OF RTS,S+TRAP MALARIA VACCINE, FORMULATED IN THE AS02A ADJUVANT SYSTEM, IN INFANT RHESUS MONKEYS
Am J Trop Med Hyg, May 1, 2004; 70(5): 499 - 509.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society of Tropical Medicine and Hygiene.